Jpmorgan Chase & CO Centogene N.V. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Centogene N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 13 shares of CNTG stock, worth $4. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 13 -0.0%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.63 - $1.63 $540 - $1,398	-858 Reduced 98.51%	13 $0
Q4 2022 Feb 13, 2023	BUY	$0.72 - $0.97 $239 - $322	332 Added 61.6%	871 $1,000
Q3 2022 Nov 14, 2022	BUY	$1.21 - $2.78 $636 - $1,462	526 Added 4046.15%	539 $1,000
Q2 2022 Aug 11, 2022	SELL	$2.06 - $4.25 $477 - $986	-232 Reduced 94.69%	13 $0
Q1 2022 May 11, 2022	SELL	$3.3 - $5.44 $23,245 - $38,319	-7,044 Reduced 96.64%	245 $1,000

Q4 2021 Feb 10, 2022	BUY	$4.56 - $10.56 $30,287 - $70,139	6,642 Added 1026.58%	7,289 $37,000
Q3 2021 Nov 12, 2021	BUY	$9.9 - $11.72 $6,405 - $7,582	647 New	647 $7,000

Others Institutions Holding CNTG

# of Institutions

Shares Held

2.14M

Call Options Held

Put Options Held

View Full List

About Centogene N.V.

Ticker CNTG
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 27,081,600
Market Cap $10.3M
Description
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare dise...

More about CNTG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account